Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Semaglutide and Weight Loss in Menopause

Weight Loss After Bariatric Surgery

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

How Does Semaglutide Work to Lose Weight?

Military Diet: Health Risks

Unexplained Weight Loss: When It Might Signal a Health Problem

Does Cinnamon Help with Weight Loss?

Wegovy: A Breakthrough in Weight Loss?

Vegetarian Diets for Weight Loss

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

See more featured articles »

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

The Natural Molecule That Could Rival Ozempic

Cachexia and Cancer

Circadian Rhythm and Weight Loss

Cachexia / Wasting Syndrome

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Mental Health Disorders, Weight Gain, and Exercise

How Oral GLP-1 Drugs Work For Weight Loss

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Latest Weight Loss News and Research

Ongoing nausea in pregnancy may flag anxiety and depression risk

Persistent or severe nausea during pregnancy was linked to higher maternal anxiety and depressive symptoms across gestation. The study found little consistent evidence that nausea worsened most perinatal outcomes, suggesting it may serve mainly as a clinical warning sign for psychological burden.

25 May 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Researchers link surgical weight loss to reduced female cancer mortality rates

Substantial and sustained weight-loss has been linked to a reduced risk of cancer and cancer-related death, mainly in women. Two new studies now provide clues to why the risk is reduced - and suggest that gender, metabolism and genetics may play a crucial role.

25 May 2026

Semaglutide helps patients who gain weight after bariatric surgery

New UCL research supports use of the weight loss drug semaglutide for patients who do not get enough benefit from bariatric surgery.

22 May 2026

NIH researchers discover how weight-loss drugs alter brain cells

A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now.

22 May 2026

Weight loss helps older AF patients slim down, but does not ease symptoms

An 8-month low-calorie diet plus behavioral support helped older adults with overweight or obesity and persistent atrial fibrillation lose weight safely, with no intervention-related serious adverse events. However, the LOSE-AF trial found no meaningful improvement in AF symptoms, rhythm control, AF burden, cardiac remodeling, or further AF procedure rates compared with usual care.

22 May 2026

Study supports routine childhood screening for type 1 diabetes

For ten years, the Fr1da study, coordinated by Helmholtz Munich, has been investigating whether early stages of type 1 diabetes in children can be detected in routine pediatric care.

21 May 2026

HonorHealth Research Institute tests steam therapy for diabetes treatment

HonorHealth Research Institute is looking to become the first research facility in the nation to begin a new clinical trial that aims to modify the lining of the digestive tract with the use of steam energy to control type II diabetes without the use of drugs.

21 May 2026

First-of-its-kind pregnancy hormone test reveals why female IBD patients face severe symptom flares

Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn's disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated.

21 May 2026

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

The nanomotor starts with bowl‑shaped mesoporous polydopamine (PDA) nanoparticles. These biocompatible bowls are loaded with two key payloads: Fe(II) ions as a Fenton catalyst, and BNN6, a thermally sensitive NO donor.

21 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Researchers identity patients with exceptional tirzepatide response outcomes

Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally.

19 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026

Obesity drugs and surgery linked to greater fat-free mass loss

A new systematic review and meta-analysis of studies presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that diet and exercise interventions result in a lower proportion of fat-free mass loss compared with obesity surgery or obesity drugs among people undergoing a weight loss of 10% or more.

13 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026